Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches.
Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain.
Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers.
The study will consist of 3 periods:
A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit.
A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders.
The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied).
Participants will make 4 visits to the clinic in person and have 4 remote (online) visits.
A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B").
There will be 3 in person visits and 4 remote visits.
Participants will need to complete an e-diary and questionnaires throughout the study.
Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.
The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria :
Exclusion Criteria :
History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache.
Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted.
Use of any of the following medications in the specified timeframe prior to start of the screening daily headache eDiary:
a. Within 24 weeks
b. Within 12 weeks
c. Within 4 weeks
Note: participants are permitted to take one concomitant migraine preventative treatment (not listed above); however, the dose of this medication should be stable for ≥3 months before start of the screening eDiary.
• Known history of treatment failure to more than four medications prescribed for the prevention of migraine (two of which have different mechanisms of action) or known history of treatment failure to botulinum toxin prescribed for the prevention of migraine.
Primary purpose
Allocation
Interventional model
Masking
714 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Ipsen Clinical Study Enquiries
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal